A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

NCT07199777 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Edema
DME

Interventions

DRUG: SNP318
DRUG: Placebo

Sponsor

SciNeuro